Navigation Links
EntreMed Reports Third Quarter 2010 Financial Results
Date:11/12/2010

reflected in our third quarter results.  During the third quarter, we successfully completed a strategic financing with fundamental investors who believe in the potential of ENMD-2076. This additional equity is instrumental in extending our cash runway through 2011.  In addition to our cash and short-term investments, EntreMed has been awarded a Qualifying Therapeutic Discovery Project (QTDP) grant in the amount of $244,479 based on its application for ENMD-2076. We are pleased that our multi-center Phase 2 study for ENMD-2076 in ovarian cancer patients is progressing as planned and we anticipate the presentation of clinical data early in 2011.  We remain enthusiastic about the potential for ENMD-2076 in solid and hematological malignancies and look forward to further expanding the clinical development program for this exciting drug candidate."

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Receives Notice of NASDAQ Compliance
2. EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China
3. EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
4. EntreMed Reports Second Quarter 2010 Financial Results
5. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
6. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
7. EntreMed Presents Initial Clinical Results for ENMD-2076
8. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
9. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
10. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
11. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
(Date:8/28/2014)... Telik, Inc. (OTCQB: TELK), a clinical ... MabVax Therapeutics, Inc. on July 8, 2014, announced ... the development of its lead antibody program designated ... Company,s internally developed antibody discovery platform.  These preclinical ... based therapeutic and diagnostic products based on this ...
(Date:8/28/2014)... 2014  Rx Safes, Inc., the manufacturer of fingerprint ... waging a new war on drugs to reduce prescription ... More than 2,500 children a day experiment with ... are easily accessed from unsecured medicine cabinets, closets and drawers. ... streets, Rx Safes will address the new age drug ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Rx Safes, Inc. Announces New War On Drugs 2
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:8/28/2014)... To kick off the fall season ... One Spas retailers across the country are offering 0% ... The Hot Tub Tailgate Event is from August 29th-September ... more information and to apply early! , As the ... wide variety of outdoor hot tubs with exclusive features ...
(Date:8/28/2014)... Somerset, N.J. (PRWEB) August 28, 2014 ... of advanced delivery technologies and development solutions for ... that Kristen DeVito, Global Director Clinical Supply Services, ... will present “Critical Path Sourcing Strategies for Active ... Trials Supply Conference, which takes place on the ...
(Date:8/28/2014)... nasal septum cells. Researchers at the University and the ... the nasal septum are able to adapt to the ... articular cartilage defects. The nasal cartilage cells, ability to ... with the expression of so-called HOX genes. The scientific ... research results together with the report of the first ...
(Date:8/28/2014)... who identify themselves as ,old, feel worse about their ... lower value than younger age groups. , New research ... old and ill, across different countries: social status, age ... the European Social Survey. Respondents, who were all aged ... The researchers found that those living in societies where ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 BCC Research ... SURGICAL NAVIGATION SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , the ... $419.7 million in 2013. Driven by the need for ... medical tourism in emerging geographies, the market is expected ... growth rate (CAGR) of 8.5% from 2013 through 2018. ...
Breaking Medicine News(10 mins):Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3
... In order to expand the range and reach of its affiliate ... Network this February. This is in addition to the company,s already ... ... Diego, CA (PRWEB) March 26, 2009 -- In order to expand ...
... a protein that helps prevent tumours spreading and growing ... many different types of cancer. In a study published ... , Canadian researchers modified the tumour inhibiting protein, von ... growth in mice. , When solid tumours grow they ...
... March 25 While dollars for infrastructure and construction ... becoming known that nearly $22 billion in stimulus funds ... across the nation. As the federal government works to ... Reinvestment Act of 2009 will be allocated, ...
... The U.S. Agency for International Development,s (USAID) ... providing more than $3.7 million in assistance to ... of families in Senegal.Of this $3.7 million, USAID ... efforts and agriculture production in the regions of ...
... The California Transplant Donor Network today issued the following statement on ... the line of duty: "Our hearts go out to the family ... community. Officer Hege was registered on the Donate Life California ... chose in death as he did in life to help those ...
... Demonstration on Anakam,s Authentication SolutionsSAN DIEGO, March 25 Anakam,s ... John Macaulay will be giving a presentation on two-factor authentication ... Place. The presentation will take place at 4:15 p.m. ... discussing issues healthcare faces in the age of electronic health ...
Cached Medicine News:Health News:TestCountry.com Expands Its Affiliate Reach with Google Affiliate Network 2Health News:TestCountry.com Expands Its Affiliate Reach with Google Affiliate Network 3Health News:Bioengineered proteins: Trial confirms new way to tackle cancer 2Health News:GlobalMedia Provides Free Grant Writing and Application Assistance to Healthcare Providers and Professionals Seeking Their Share of Billions in Economic Stimulus Dollars 2Health News:California Transplant Donor Network Issues Statement on Officer John Hege's Donation 2Health News:Dr. William 'Bill' Braithwaite and Dr. John Macaulay Present Anakam's Two-Factor Authentication Platform at HIMSS 2009 Annual Conference and Exhibition 2
BETADINE Solution Swab Aid antiseptic pads are for quick and easy skin degerming. Individually wrapped pads, saturated with 10% povidone-iodine solution, offer the advantages of BETADINE Solution in ...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
Medicine Products: